ClinicalTrialsFinder
RecruitingNCT06598982

Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis

Sponsor

Selcuk University

Enrollment

85 participants

Start Date

Jul 1, 2024

Study Type

OBSERVATIONAL

Conditions

SclerodermaSystemic Sclerosis (SSc)

Summary

The aim of this study was to investigate respiratory muscle sarcopenia in individuals with systemic sclerosis. The main question it aims to answer is: What is the prevalence of respiratory muscle sarcopenia in patients with systemic sclerosis? Participants body composition (bioelectrical impedance), hand grip strength (hand dynanometer), physical performance tests (5 repetition sit-and-stand test, 4-meter walk test, Timed up-and-go test) and respiratory muscle strength were evaluated.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria4

  • Being between the ages of 18-75
  • To be diagnosed with systemic sclerosis according to ACR/EULAR classification criteria
  • Being clinically stable
  • Ability to adapt to tests (visual, cognitive, cooperative)

Exclusion Criteria6

  • Those with neurological and/or musculoskeletal problems that may affect the work
  • Presence of severe joint contracture or painful ulcers that may affect muscle strength measurement and walking
  • Presence of severe infection or sepsis
  • Being diagnosed with a known additional rheumatologic disease
  • Any stage of cancer
  • Pregnant or breastfeeding

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Selcuk University

Konya, Selcuklu, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06598982

Related Trials

Intralesional Injection of STS in Treatment of Calcinosis

NCT066728221 location

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

NCT070856761 location

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT0630897818 locations

Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）

NCT068011191 location

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT0632877710 locations